[144] Enova International, Inc. SEC Filing

Rhea-AI Filing Summary

Enova International, Inc. Form 144 notice shows a proposed sale of 5,000 common shares through Merrill Lynch (Chicago) with an aggregate market value of $575,000, to be sold approximately on 08/26/2025 on the NYSE. The filer indicates these 5,000 shares were originally acquired on 02/12/2019 from Enova International via stock options. The filing also discloses two recent sales by the same person within the past three months: 2,000 shares sold on 06/20/2025 for $196,762.87 and 5,000 shares sold on 07/14/2025 for $575,951.66. The form includes a representation that the seller does not possess undisclosed material adverse information and references Rule 10b5-1 planning language.

Positive

• The filing discloses a proposed sale with specific broker details (Merrill Lynch) and a clear aggregate market value of $575,000 for transparency.
• The securities were acquired via stock options on 02/12/2019, indicating proceeds are from option monetization rather than new issuance.
• Prior sales within the past three months are disclosed (2,000 and 5,000 shares), demonstrating ongoing compliance with reporting rules.

Negative

• An insider is selling shares (totaling 12,000 shares including the proposed sale and past three months), which may be viewed negatively by some investors despite being a small fraction of outstanding shares.

Insights

Securities Analyst

TL;DR: Routine insider sale disclosure; amounts are modest relative to total shares outstanding and show ongoing liquidity events.

The Form 144 reports a proposed near-term sale of 5,000 Enova common shares valued at $575,000, using Merrill Lynch as broker, and notes two recent dispositions totaling 7,000 shares in the past three months for roughly $772,714.53 in gross proceeds. The reporting party acquired the disclosed shares via stock options in 2019, which indicates these are not newly issued shares but option-originated shares being monetized. With 25,012,613 shares outstanding, the disclosed transactions represent a small fraction of the float, making the filing informational rather than balance-sheet altering. The signature/representation language and Rule 10b5-1 mention suggest standard compliance steps.

Corporate Governance Specialist

TL;DR: Disclosure aligns with Rule 144 requirements; no signs of undisclosed material information but indicates insider selling activity.

The filing fulfills Rule 144 notice obligations by specifying broker, amounts, acquisition source (stock options), and recent prior sales by the same person. The inclusion of the seller's attestation regarding material information and the option/plan reference implies routine governance compliance. While insider sales can attract investor attention, the absolute and relative sizes here are small versus total shares outstanding, and the form contains no additional governance or regulatory red flags.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 110 N Wacker Dr Ste 1900 Chicago IL 60606	5000	575000.00	25012613	08/26/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/12/2019	Stock Options	Enova International			5000	02/12/2019	Stock Option

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Fisher 175 West Jackson Blvd, Suite 600 Chicago IL 60604	Common	06/20/2025	2000	196762.87
David Fisher 175 West Jackson Blvd Suite 600 Chicago IL 60604	Common	07/14/2025	5000	575951.66

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ENVA Form 144 disclose about the proposed sale?

The form discloses a proposed sale of 5,000 Enova common shares via Merrill Lynch on the NYSE for an aggregate market value of $575,000, approximately on 08/26/2025.

How were the shares being sold acquired according to the filing?

The filing states the 5,000 shares were acquired on 02/12/2019 through stock options issued by Enova International.

Have there been recent sales by the same person?

Yes. The filing reports sales of 2,000 shares on 06/20/2025 for $196,762.87 and 5,000 shares on 07/14/2025 for $575,951.66.

How large are these transactions relative to Enova's outstanding shares?

The form lists 25,012,613 shares outstanding; the proposed 5,000-share sale is a very small fraction of that total.

Does the filer claim to hold any undisclosed material information?

By signing the notice the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.